Dermalive is a cosmetic filler injected into the skin to smooth out wrinkles and other cosmetic defects. It is alleged that the French manufacturer, Dermatech, and the Canadian distributors, Intradermal Distribution and Vivier Pharma, failed to warn patients and their physicians of the true risks associated with the use of Dermalive.

Nearly eleven thousand units of Dermalive were sold in Canadafrom 2003 until 2007 when sales in Canada were suspended. Patients world-wide have experienced various degrees of granulomatous reaction, a condition which can leave painful and disfiguring lumps, scarring and permanent disability such as the inability to smile. In many cases of granulomas, there is no cure.

Developments

Update: Dermalive Class Action Settlement Finalized

The Settlement: On October 10, 2014, Mr. Justice Sewell of the Supreme Court of British Columbia approved the settlement of a class action for people who developed granulomas after being injected with Dermalive. Dermalive is a cosmetic filler injected into the skin to smooth out wrinkles and other cosmetic defects. The settlement provides compensation to individuals who establish that they were injected with Dermalive in Canada and developed granulomas in the area injected with Dermalive. Money is also available to reimburse the cost of corrective medical treatment (e.g., steroid injections, laser treatments, surgery, etc.). The settlement applies to residents of British Columbia who did not opt out of the class action on or before February 15, 2014 and non-BC residents who validly opted into the class action on or before February 15, 2014.

Getting Information: For more information about making a claim, contact the Administrator: